iBio, Inc. financial data

Symbol
IBIO on NYSE
Industry
Pharmaceutical Preparations
Location
600 Madison Avenue, Suite 1601, New York, New York
State of incorporation
Delaware
Fiscal year end
June 30
Former names
iBioPharma, Inc. (to 8/14/2009), InB:Biotechnologies, Inc. (to 7/17/2008)
Latest financial report
Q1 2024 - May 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 123 % -20.1%
Quick Ratio 0 %
Debt-to-equity 160 % +79.7%
Return On Equity -205 % -487%
Return On Assets -109 % -336%
Operating Margin -53.6 K % -2906%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8.62 M shares -48.7%
Common Stock, Shares, Outstanding 8.52 M shares -31.1%
Entity Public Float 5.44 M USD -95.5%
Common Stock, Value, Issued 9 K USD -43.8%
Weighted Average Number of Shares Outstanding, Basic 3.71 M shares +463%
Weighted Average Number of Shares Outstanding, Diluted 3.71 M shares +463%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 50 K USD -97.2%
Revenue from Contract with Customer, Excluding Assessed Tax 50 K USD
Research and Development Expense 6.4 M USD -44.5%
General and Administrative Expense 11.8 M USD -49.2%
Operating Income (Loss) -18.2 M USD +47.8%
Nonoperating Income (Expense) 1.06 M USD +1484%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -76 M USD -129%
Earnings Per Share, Basic 70.7 USD/shares +92.3%
Earnings Per Share, Diluted 70.7 USD/shares +92.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.3 M USD -19.2%
Cash, Cash Equivalents, and Short-term Investments 6.43 M USD -34.5%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Inventory, Net 0 USD
Assets, Current 36.1 M USD +33.4%
Property, Plant and Equipment, Net 3.73 M USD -14.5%
Operating Lease, Right-of-Use Asset 2.47 M USD -11.3%
Intangible Assets, Net (Excluding Goodwill) 5.37 M USD -0.37%
Assets 50.2 M USD +13%
Accounts Payable, Current 1.23 M USD -39%
Employee-related Liabilities, Current 3.35 M USD +9.33%
Accrued Liabilities, Current 4 M USD +4.63%
Contract with Customer, Liability, Current 175 K USD
Liabilities, Current 21.4 M USD -3.82%
Operating Lease, Liability, Noncurrent 2.8 M USD -13.1%
Liabilities 25.3 M USD -6.32%
Accumulated Other Comprehensive Income (Loss), Net of Tax -167 K USD -83.5%
Retained Earnings (Accumulated Deficit) -306 M USD -8.19%
Stockholders' Equity Attributable to Parent 24.9 M USD +43%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 24.9 M USD +43%
Liabilities and Equity 50.2 M USD +13%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.34 M USD +61.7%
Net Cash Provided by (Used in) Financing Activities 2.47 M USD +117%
Net Cash Provided by (Used in) Investing Activities 50 K USD +72.4%
Common Stock, Shares Authorized 275 M shares 0%
Common Stock, Shares, Issued 8.52 M shares -46.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.82 M USD +78%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.43 M USD -34.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 200 K USD +6.95%
Deferred Tax Assets, Valuation Allowance 49.6 M USD +34.8%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Depreciation 165 K USD -39.1%
Payments to Acquire Property, Plant, and Equipment 5.74 M USD -21.7%
Lessee, Operating Lease, Liability, to be Paid 3.23 M USD -10.5%
Property, Plant and Equipment, Gross 4.62 M USD +0.57%
Operating Lease, Liability, Current 424 K USD +12.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 476 K USD +12.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 424 K USD +12.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, to be Paid, Year Three 532 K USD +11.8%
Deferred Tax Assets, Operating Loss Carryforwards 43 M USD +19.9%
Preferred Stock, Shares Issued 0 shares
Deferred Federal Income Tax Expense (Benefit) -12.2 M USD -34.3%
Current Income Tax Expense (Benefit) 0 USD
Preferred Stock, Shares Authorized 1 M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 593 K USD +11.5%
Operating Lease, Payments 564 K USD -5.37%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 20 K USD -89.4%
Share-based Payment Arrangement, Expense 2.11 M USD -39.6%
Deferred State and Local Income Tax Expense (Benefit) -637 K USD
Interest Expense 52 K USD +48.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%